| RWIAX | VICCX | RWIAX / VICCX | |
| Total Expense Ratio | 1.51 | 2.48 | 61% |
| Annual Report Gross Expense Ratio | 1.51 | 2.65 | 57% |
| Fund Existence | 24 years | 15 years | - |
| Gain YTD | 15.218 | 4.600 | 331% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 250 | 2000 | 13% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 160B | 51.2M | 312,500% |
| Annual Yield % from dividends | 0.73 | 0.24 | 306% |
| Returns for 1 year | 20.85 | -3.08 | -677% |
| Returns for 3 years | 49.70 | -5.62 | -884% |
| Returns for 5 years | 31.19 | -31.21 | -100% |
| Returns for 10 years | 102.34 | -28.84 | -355% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| CSHZX | 13.70 | 0.15 | +1.11% |
| NYLI Cushing® MLP Premier Class I | |||
| FSMAX | 116.33 | N/A | N/A |
| Fidelity Extended Market Index | |||
| ACIZX | 66.86 | N/A | N/A |
| Alger Capital Appreciation Instl Z-2 | |||
| BIPIX | 80.88 | N/A | N/A |
| ProFunds Biotechnology UltraSector Inv | |||
| TASVX | 22.54 | N/A | N/A |
| PGIM Quant Solutions Small-Cap Val Z | |||